Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial-Reference-Cited by-同舟云学术

Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial

Published:2024 Issue: Volume: Page:
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Harada-Shiba Mariko¹,Davdison Michael H.²,Ditmarsch Marc²,Hsieh Andrew²,Wuerdeman Erin²,Kling Douglas²,Nield Annie²,Dicklin Mary R.³,Nakata Akitaka⁴,Sueyoshi Atsushi⁵,Kuroyanagi Satoshi⁶,Kastelein John J.P.²

Affiliation:

1. Cardiovascular Center, Osaka Medical and Pharmaceutical University

2. NewAmsterdam Pharma B.V.

3. Midwest Biomedical Research

4. Department of Cardiology, Sanai Hospital

5. Department of Diabetes Internal Medicine, Uji-Tokushukai Medical Center

6. Department of Cardiovascular Surgery, Kishiwada Tokushukai Hospital

Publisher

Japan Atherosclerosis Society

Link

https://www.jstage.jst.go.jp/article/jat/advpub/0/advpub_64828/_pdf

Reference29 articles.

1. 1) Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Jr., Sperling L, Virani SS and Yeboah J: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019; 139: e1082-e1143

2. 2) Virani SS, Aspry K, Dixon DL, Ferdinand KC, Heidenreich PA, Jackson EJ, Jacobson TA, McAlister JL, Neff DR, Gulati M and Ballantyne CM: The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Preventive Cardiology. J Clin Lipidol, 2023; 17: 208-218

3. 3) Wang N, Woodward M, Huffman MD and Rodgers A: Compounding Benefits of Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events: Systematic Review and Meta-Analysis. Circulation: Cardiovascular Quality and Outcomes, 2022; 15: e008552

4. 4) Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, Murphy J, Banach M, De Servi S, Gaita D, Gouni-Berthold I, Hovingh GK, Jozwiak JJ, Jukema JW, Kiss RG, Kownator S, Iversen HK, Maher V, Masana L, Parkhomenko A, Peeters A, Clifford P, Raslova K, Siostrzonek P, Romeo S, Tousoulis D, Vlachopoulos C, Vrablik M, Catapano AL, Poulter NR and study DV: EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol, 2021; 28: 1279-1289

5. 5) Nelson AJ, Haynes K, Shambhu S, Eapen Z, Cziraky MJ, Nanna MG, Calvert SB, Gallagher K, Pagidipati NJ and Granger CB: High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S. J Am Coll Cardiol, 2022; 79: 1802-1813

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Randomized, Parallel, Open‐Label, Single‐Dose and Multiple‐Dose Clinical Trial to Investigate the Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Obicetrapib in Healthy Participants in China;The Journal of Clinical Pharmacology;2024-08-19

2. New perspectives on the high-density lipoprotein system and its role in the prevention and treatment of atherosclerotic cardiovascular disease;Current Opinion in Endocrinology, Diabetes & Obesity;2024-08-05

3. Obicetrapib on top of maximally tolerated lipid‐modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN;American Heart Journal;2024-08

4. Obicetrapib: There is still Life in the CETP Inhibitor!;Journal of Atherosclerosis and Thrombosis;2024